Kura Oncology, Inc. (KURA)
Largest Insider Buys in Sector
KURA Stock Price History Chart
KURA Stock Performance
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable …
Insider Activity of Kura Oncology, Inc.
Over the last 12 months, insiders at Kura Oncology, Inc. have bought $0 and sold $2.1M worth of Kura Oncology, Inc. stock.
On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $575,000 and sold $7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $575,000 was made by Malley Thomas (director) on 2023‑06‑16.
List of Insider Buy and Sell Transactions, Kura Oncology, Inc.
| 2024-11-18 | Sale | Chief Operating Officer | 526 0.0007% | $16.03 | $8,434 | -0.27% | ||
| 2024-05-20 | Sale | Chief Legal Officer | 2,615 0.0034% | $22.15 | $57,916 | -9.41% | ||
| 2024-01-30 | Sale | Chief Medical Officer | 4,825 0.0067% | $21.55 | $103,980 | -2.63% | ||
| 2024-01-29 | Sale | Chief Legal Officer | 2,053 0.0027% | $17.80 | $36,544 | +9.67% | ||
| 2024-01-29 | Sale | SVP, Finance & Accounting | 2,318 0.003% | $17.80 | $41,262 | +9.67% | ||
| 2024-01-29 | Sale | Chief Medical Officer | 7,158 0.0093% | $17.80 | $127,416 | +9.67% | ||
| 2024-01-29 | Sale | Chief Operating Officer | 1,496 0.0019% | $17.80 | $26,630 | +9.67% | ||
| 2024-01-24 | Sale | President and CEO | 84,107 0.1166% | $20.23 | $1.7M | +3.66% | ||
| 2023-06-16 | director | 50,000 0.0781% | $11.50 | $575,000 | +13.75% | |||
| 2023-01-27 | Sale | Chief Medical Officer | 9,225 0.0138% | $13.88 | $128,033 | -19.28% | ||
| 2023-01-27 | Sale | Chief Operating Officer | 1,821 0.0027% | $13.89 | $25,294 | -19.28% | ||
| 2023-01-27 | Sale | CCO & Chief Strategy Officer | 1,906 0.0029% | $13.89 | $26,474 | -19.28% | ||
| 2023-01-27 | Sale | SVP, Finance & Accounting | 1,548 0.0023% | $13.89 | $21,502 | -19.28% | ||
| 2021-03-15 | Sale | Chief Operating Officer | 6,250 0.0095% | $29.43 | $183,951 | -36.81% | ||
| 2020-12-15 | Sale | Chief Operating Officer | 9,375 0.0161% | $40.60 | $380,667 | -46.25% | ||
| 2020-11-10 | Sale | Chief Operating Officer | 6,250 0.0107% | $39.43 | $246,438 | -37.05% | ||
| 2020-10-08 | Sale | President and CEO | 157,106 0.2753% | $34.00 | $5.34M | -16.38% | ||
| 2020-10-07 | Sale | President and CEO | 99,900 0.1621% | $32.00 | $3.2M | -17.58% | ||
| 2020-10-06 | Sale | President and CEO | 100 0.0002% | $32.00 | $3,200 | -10.97% | ||
| 2020-09-15 | Sale | Chief Operating Officer | 6,250 0.0115% | $29.43 | $183,938 | +1.34% |
Insider Historical Profitability
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4408097 5.6686% | $15.80 | 8 | 1 | +14.44% |
| Malley Thomas | director | 139557 0.1795% | $15.80 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Suvretta Capital Management, LLC | $150.8M | 9.28 | 7.07M | +1.78% | +$2.63M | 6.37 | |
| BlackRock | $147.16M | 9.06 | 6.9M | -5.69% | -$8.88M | <0.01 | |
| Ecor1 Capital Llc | $123.86M | 7.62 | 5.81M | 0% | +$0 | 0.87 | |
| Deerfield Management | $115.43M | 7.1 | 5.41M | +1.86% | +$2.11M | 0.28 | |
| Bvf Inc Il | $102.09M | 6.28 | 4.79M | -35.09% | -$55.18M | 0.75 |